Qualified Persons
“At Chartered Pharma Consultants, we collaborate with clients to develop and execute streamlined functional strategies that ensure long-lasting compliance by seamlessly integrating technical, scientific, and regulatory knowledge.”
“At Chartered Pharma Consultants, we collaborate with clients to develop and execute streamlined functional strategies that ensure long-lasting compliance by seamlessly integrating technical, scientific, and regulatory knowledge.”
Daily news
Everything about the business world in one place.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
Ljilja Peltola Consultant
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tem por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
Cedric Xiong Ceo
Best deals
Special offer worth investing in, choose your pack today!
Dr Durgaprasad Seeram
Director / Senior Consultant
Daniel Dooley
Director of GxP services / Senior Consultant
Dr John Folan
Qualified Person (EU) / Senior Consultant
Puneet Kumar
Qualified person (U.K.) / Senior Consultant
Richard Baitson
Lead Auditor / Senior Consultant
QA & Regulatory Specialists
Bottom Line: Tiered Impact Under the Omnibus CSDDD (Pharma)
Your tiered model holds up well under the Omnibus approach and aligns with how the directive is intended to operate in practice. What This Really Means The Omnibus model reinforces
Key Takeaway: What Omnibus CSDDD Really Means for Pharma
The Omnibus proposal can be distilled into a clear regulatory principle: “Focus on direct suppliers, and only go deeper when risk justifies it.” At face value, this suggests a
CSDDD Omnibus in Practice: What It Means for Pharma Supply Chains
The proposed Omnibus revisions to the Corporate Sustainability Due Diligence Directive (CSDDD) become much clearer when applied to real-world industry structures. In the pharmaceut
CSDDD Omnibus Update Explained: Scope, Thresholds, and What’s Changing
As the European Union refines its sustainability framework, the proposed “Omnibus” revisions to the Corporate Sustainability Due Diligence Directive (CSDDD) signal a clear shif
CSDDD Omnibus Explained: What the Corporate Sustainability Due Diligence Directive Really Covers
The Corporate Sustainability Due Diligence Directive (CSDDD) is one of the European Union’s most significant regulatory steps toward holding companies accountable for their impac
What truly defines a “Successful” Manager?
In the evolving landscape of leadership, we often debate what makes a manager truly effective. Is it deep technical expertise? Is it soft skills? Or is it something else entirely
FDA Warning Letter to Abbott Diabetes Care — Key Quality System Failures
Recently the U.S. Food and Drug Administration issued a Warning Letter to Abbott Diabetes Care following a routine inspection of their Alameda, CA facility that raised serious Qual
FDA Form 483 Deep Dive: Sterile Manufacturing Under the Microscope.
The U.S. Food and Drug Administration (FDA) issued a Form 483 to Eugia Pharma Specialities Limited, Sangareddy, Telangana, 502307 India following a January–February 2026 inspect
The True Cost of Non-Compliant Promotion of Medicinal Products…
Recent years have provided stark reminders of the financial, regulatory, and societal consequences of failures in pharmaceutical compliance and governance. 🔶 One widely cited ex
